Valpromide

Jump to: navigation, search
This image is provided by the National Library of Medicine.

WikiDoc Resources for Valpromide

Articles

Most recent articles on Valpromide

Most cited articles on Valpromide

Review articles on Valpromide

Articles on Valpromide in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Valpromide

Images of Valpromide

Photos of Valpromide

Podcasts & MP3s on Valpromide

Videos on Valpromide

Evidence Based Medicine

Cochrane Collaboration on Valpromide

Bandolier on Valpromide

TRIP on Valpromide

Clinical Trials

Ongoing Trials on Valpromide at Clinical Trials.gov

Trial results on Valpromide

Clinical Trials on Valpromide at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Valpromide

NICE Guidance on Valpromide

NHS PRODIGY Guidance

FDA on Valpromide

CDC on Valpromide

Books

Books on Valpromide

News

Valpromide in the news

Be alerted to news on Valpromide

News trends on Valpromide

Commentary

Blogs on Valpromide

Definitions

Definitions of Valpromide

Patient Resources / Community

Patient resources on Valpromide

Discussion groups on Valpromide

Patient Handouts on Valpromide

Directions to Hospitals Treating Valpromide

Risk calculators and risk factors for Valpromide

Healthcare Provider Resources

Symptoms of Valpromide

Causes & Risk Factors for Valpromide

Diagnostic studies for Valpromide

Treatment of Valpromide

Continuing Medical Education (CME)

CME Programs on Valpromide

International

Valpromide en Espanol

Valpromide en Francais

Business

Valpromide in the Marketplace

Patents on Valpromide

Experimental / Informatics

List of terms related to Valpromide

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Valpromide (marketed as Depamide by Sanofi-Aventis) is a carboxamide derivative of valproic acid used in the treatment of epilepsy and some affective disorders. It is rapidly metabolised (80%) to valproic acid (another anticonvulsant) but has anticonvulsant properties itself. It may produce more stable plasma levels than valproic acid or sodium valproate and may be more effective at preventing febrile seizures. However, it is over one hundred times more potent as an inhibitor of liver microsomal epoxide hydrolase. This makes it incompatible with carbamazepine and can affect the ability of the body to remove other toxins. Valpromide is no safer during pregnancy than valproic acid.

Valpromide is formed through the reaction of valproic acid and ammonia via an intermediate acid chloride.

In pure form, valpromide is a white crystalline powder and has melting point 125–126 °C. It is practically insoluble in water but soluble in hot water. It is available on the market in some European countries.

See also

References

  • The Medical Treatment of Epilepsy by Stanley R Resor. Published by Marcel Dekker (1991). ISBN 0-8247-8549-5.
  • Hydrolysis in Drug and Prodrug Metabolism: Chemistry, Biochemistry, and Enzymology by Bernard Testa, Joachim M. Mayer (2003). ISBN 3-906390-25-X.
  • In Vitro Methods in Developmental Toxicology by Gary L Kimmel, Devendra M Kochhar, Baumann (1989). ISBN 0-8493-6919-3.

Linked-in.jpg